Figure 3From: Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy Median absolute neutrophil count (ANC) by day in chemotherapy cycle 1 (per-protocol population). Back to article page